KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Net Cash Flow (2016 - 2025)

Gilead Sciences (GILD) has disclosed Net Cash Flow for 17 consecutive years, with $229.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 95.43% year-over-year to $229.0 million, compared with a TTM value of -$2.5 billion through Dec 2025, down 163.84%, and an annual FY2025 reading of -$2.5 billion, down 163.84% over the prior year.
  • Net Cash Flow was $229.0 million for Q4 2025 at Gilead Sciences, down from $2.2 billion in the prior quarter.
  • Across five years, Net Cash Flow topped out at $5.0 billion in Q4 2024 and bottomed at -$2.9 billion in Q2 2025.
  • Average Net Cash Flow over 5 years is $77.8 million, with a median of $130.5 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 31614.29% in 2024, while the deepest fall reached 356.63% in 2024.
  • Year by year, Net Cash Flow stood at $985.0 million in 2021, then plummeted by 35.23% to $638.0 million in 2022, then crashed by 46.24% to $343.0 million in 2023, then surged by 1360.64% to $5.0 billion in 2024, then plummeted by 95.43% to $229.0 million in 2025.
  • Business Quant data shows Net Cash Flow for GILD at $229.0 million in Q4 2025, $2.2 billion in Q3 2025, and -$2.9 billion in Q2 2025.